(via TheNewswire)
The following resolutions were proposed and approved at the AGM:
Dr.
Philip M. Toleikis ,James T. Parsons ,Deborah M. Brown , Dr.Mohammad Azab , Dr.Daniel Mahony ,Brett Whalen , Dr.Steven Sangha andBertram von Plettenberg were elected as directors of the Corporation for the ensuing year.Appointment of
KPMG LLP , as auditors of the Company until the next annual meeting and the authorization of the directors of the Company to fix the remuneration to be paid to the auditors.
The resolution to ratify and confirm amendments to the Option Plan and DSU Plan and to increase the maximum number of Common Shares reserved for issuance was not tabled at the AGM and as such the current incentive plan without the amendments continues in effect.
“As they transition out of their director roles, I would like to acknowledge
“We are honored to be given the opportunity to represent the voice of all shareholders. As directors on the Board of
ABOUT
FOR FURTHER INFORMATION, PLEASE CONTACT:
Corporate:
VP, Investor Relations
christopher.barnes@sernova.com
519-902-7923
www.sernova.com
Investors:
cdavis@lifesciadvisors.com
212-915-2577
Media:
emiller@lifescicomms.com
646-791-9705
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements.
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source